EUVIMEDEUVIMED entdecken
Open Access

PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series

Patricia Vaduva iD, Lucas Bouys iD, Anne Jouinot, Stephanie Espiard, Albain Chansavang, Annabel Berthon iD, Mario Néou, Anna Vaczlavik, Florian Violon iD, Helaine Charchar, Matthias Kroiss, Gerald Raverot iD und 11 weitere

The Journal of Clinical Endocrinology & Metabolism · 2025

DOI: 10.1210/clinem/dgae918 ↗

Kurz gefasst

Fachartikel in der Zeitschrift The Journal of Clinical Endocrinology & Metabolism, 2025. Verfasst von Patricia Vaduva und 22 weiteren Autor:innen. Beteiligte Einrichtung: Institut Cochin, INSERM U1016, CNRS UMR8104, Paris Descartes University, Paris 75014, France. Hauptthemen laut MEDLINE: Phosphoric Diester Hydrolases. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Fondation pour la Recherche Médicale, French Society of Endocrinology, IPSEN.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Context

Primary bilateral macronodular adrenal hyperplasia (PBMAH), the most common cause of Cushing syndrome due to bilateral nodules, is a heterogeneous disease at the clinical, hormonal, and morphological levels. ARMC5-inactivating pathogenic variants are causative of PBMAH, and rare variants of PDE11A have been associated with PBMAH.

Objective

The aim of this study, on a large cohort of individuals with PBMAH from Europe and America, was to study the ARMC5 and PDE11A genotype to determine the genotype/phenotype correlation and to investigate the hypothesis that PDE11A could be a modifying gene of the adrenal phenotype.

Methods

Leukocyte DNA of 354 PBMAH index cases was sequenced for ARMC5 and PDE11A genes by next-generation sequencing. Phenotypic characteristics of 334 of these patients were analyzed to study the genotype/phenotype correlations.

Results

Seven out of 16 PDE11A variants were considered damaging according to in silico predictions: 6 missense variants (p.Tyr727Cys, p.Met623Arg, p.Tyr658Cys, p.Ag867Trp, p.Asn298Ser, p.Glu840Lys) and 1 stop-gain variant (p.Arg307Ter). In the cohort, 11.4% of patients had one of these variants and 19.2% had ARMC5-pathogenic variants. There was no statistically significant difference in the distribution of PDE11A-damaging variants according to ARMC5 status (P = .83; OR = 0.79; 95% CI, 0.26-2.03) nor in the distribution of ARMC5 pathogenic variants according to PDE11A status (P = .83; OR = 0.81; 95% CI, 0.27-2.04). Patients with PDE11A-damaging variants had lower urinary free cortisol (0.7 vs 1.25 upper limit of normal; P = .0002), midnight plasma cortisol (157.81 vs 222.19 nmol/L, P = .016), and number of adrenal nodules (3.46 vs 4.74; P = .048) compared to PDE11A wild-type patients. Patients with ARMC5-pathogenic variants had a more severe phenotype with more frequent comorbidities and were more often treated by adrenalectomy (60%).

Conclusion

PDE11A appears to be a modulator of PBMAH phenotype, damaging variants being associated with an attenuated form. This may contribute to the heterogeneity of PBMAH and could affect patient management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Phosphoric Diester HydrolasesHumansMaleFemaleMiddle AgedPhenotypeAdultGenetic Association StudiesAgedGenotypeYoung AdultAdrenal Hyperplasia, CongenitalCushing SyndromeArmadillo Domain ProteinsAdolescentCohort StudiesMutation, Missense3',5'-Cyclic-GMP Phosphodiesterases

Stichwörter der Autor:innen

ARMC5PDE11ACushing syndromephenotypeprimary bilateral macronodular adrenal hyperplasia (PBMAH)

Substanzen

PDE11A protein, humanARMC5 protein, humanPhosphoric Diester HydrolasesArmadillo Domain Proteins3',5'-Cyclic-GMP Phosphodiesterases

Autor:innen und Institutionen

  • Institut Cochin, INSERM U1016, CNRS UMR8104, Paris Descartes University, Paris 75014, France.
  • Department of Endocrinology, Reference Center for Rare Adrenal Diseases, Assistance Publique Hôpitaux de Paris, Hôpital Cochin, Paris 75014, France.
  • Department of Endocrinology, Diabetology and Metabolism, Lille University Hospital, Lille 59000, France.
  • Department of Genomic Medicine of Tumors and Cancers, Cochin Hospital, APHP, Paris 75014, France.
  • Department of Endocrinology, Adrenal Unit, University of Sao Paulo, São Paulo 03178-200, Brazil.
  • Department of Internal Medicine IV, LMU University Hospital and Ludwig-Maximilians-Universität München, Munich 80539, Germany.

ORCID-Profile: Patricia Vaduva, Lucas Bouys, Annabel Berthon, Florian Violon, Gerald Raverot, Helene Lasolle, Antoine Tabarin, Peter Kamenicky, Eric Pasmant, Jérôme Bertherat

Förderung

  • Fondation pour la Recherche Médicale
  • French Society of Endocrinology
  • IPSEN
  • National Institutes of Health

Zitieren

APA

Vaduva, P., Bouys, L., Jouinot, A., Espiard, S., Chansavang, A., Berthon, A., Néou, M., Vaczlavik, A., Violon, F., Charchar, H., Kroiss, M., Raverot, G., Lasolle, H., Guignat, L., Libé, R., Assié, G., Tabarin, A., Kamenicky, P., Pasmant, E., …, & Bertherat, J. (2025). PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series. The Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/clinem/dgae918

Vancouver

Vaduva P, Bouys L, Jouinot A, Espiard S, Chansavang A, Berthon A, et al. PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series. The Journal of Clinical Endocrinology & Metabolism. 2025. doi:10.1210/clinem/dgae918

BibTeX
@article{Vaduva2025,
  author = {Vaduva, Patricia and Bouys, Lucas and Jouinot, Anne and Espiard, Stephanie and Chansavang, Albain and Berthon, Annabel and Néou, Mario and Vaczlavik, Anna and Violon, Florian and Charchar, Helaine and Kroiss, Matthias and Raverot, Gerald and Lasolle, Helene and Guignat, Laurence and Libé, Rossella and Assié, Guillaume and Tabarin, Antoine and Kamenicky, Peter and Pasmant, Eric and Fragoso, Maria and Stratakis, Constantine and Ragazzon, Bruno and Bertherat, Jérôme},
  title = {PDE11A Is a Phenotype Modulator of Primary Bilateral Macronodular Adrenal Hyperplasia: Results of a 334-Patient Series},
  journal = {The Journal of Clinical Endocrinology & Metabolism},
  year = {2025},
  doi = {10.1210/clinem/dgae918}
}
Kostenlos starten →